GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $29.43 and traded as low as $28.42. GENMAB A/S/S shares last traded at $28.66, with a volume of 2,026,734 shares traded.
GENMAB A/S/S Stock Performance
The business’s fifty day moving average price is $29.43 and its two-hundred day moving average price is $24.41.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading
- Five stocks we like better than GENMAB A/S/S
- How to Short Nasdaq: An Easy-to-Follow Guide
- Occidental Petroleum is a Buy in Q4 2025
- How to Choose Top Rated Stocks
- 3 Beaten-Down Stocks With Rebound Potential This Earnings Season
- Are Penny Stocks a Good Fit for Your Portfolio?
- Amazon Is One of the Clearest Buys If the Market Dips Again
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
